|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018270,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0025914,
umls-concept:C0026336,
umls-concept:C0026339,
umls-concept:C0026809,
umls-concept:C0060369,
umls-concept:C0086418,
umls-concept:C0148199,
umls-concept:C0205263,
umls-concept:C0206364,
umls-concept:C1554184,
umls-concept:C1948076,
umls-concept:C1999216,
umls-concept:C2239176
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2008-10-2
|
|
pubmed:abstractText |
Hepatocellular carcinoma (HCC) is the fifth most common primary neoplasm; surgery is the only curative option but 5-year survival rates are only 25% to 50%. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are known to be involved in growth and neovascularization of HCC. Therefore, agents that target these pathways may be effective in the treatment of HCC. The aim of this study was to determine the antineoplastic activity of brivanib alaninate, a dual inhibitor of VEGF receptor (VEGFR) and FGF receptor (FGFR) signaling pathways.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AyersMarkM,
pubmed-author:ByronSaraS,
pubmed-author:ChowPierceP,
pubmed-author:ChungAlexanderA,
pubmed-author:FargnoliJosephJ,
pubmed-author:HuynhHungH,
pubmed-author:KoongHeng NungHN,
pubmed-author:NgoVan ChanhVC,
pubmed-author:OngHock SooHS,
pubmed-author:PollockPamelaP,
pubmed-author:SooKhee CheeKC,
pubmed-author:ThngChoon HuaCH,
pubmed-author:TranEvelynE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6146-53
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18829493-Alanine,
pubmed-meshheading:18829493-Animals,
pubmed-meshheading:18829493-Apoptosis,
pubmed-meshheading:18829493-Carcinoma, Hepatocellular,
pubmed-meshheading:18829493-Cell Line, Tumor,
pubmed-meshheading:18829493-Cell Proliferation,
pubmed-meshheading:18829493-Humans,
pubmed-meshheading:18829493-Liver Neoplasms,
pubmed-meshheading:18829493-Male,
pubmed-meshheading:18829493-Mice,
pubmed-meshheading:18829493-Models, Chemical,
pubmed-meshheading:18829493-Neoplasm Transplantation,
pubmed-meshheading:18829493-Neovascularization, Pathologic,
pubmed-meshheading:18829493-Receptors, Fibroblast Growth Factor,
pubmed-meshheading:18829493-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:18829493-Triazines
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
|
|
pubmed:affiliation |
Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore, Singapore. cmrhth@nccs.com.sg
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
